Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front Med    2011, Vol. 5 Issue (4) : 333-335     DOI: 10.1007/s11684-011-0166-2
MINI-REVIEW |
Overcoming the challenges of conducting translational research in cell therapy
Sowmya Viswanathan1(), Armand Keating1,2
1. Cell Therapy Program, Princess Margaret Hospital, University Health Network, Toronto, ON, M5G 2M9, Canada; 2. Division of Hematology, Department of Medicine, University of Toronto,Toronto, ON, M5G 2M9, Canada
Download: PDF(69 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  

Cell therapy holds promise in addressing a number of unmet medical needs but despite its considerable impetus, faces numerous challenges including support for translational research in this area. Here, we examine the challenges confronting cell therapy research including the limited funding available for translational research partly due to the uncompetitive nature of required validation studies in cell therapy that of necessity are not hypothesis-driven. Other issues include lack of standardization of definitions of cell products, uncertainty regarding optimum preclinical animal models, duplication of efforts to secure regulatory approval and a lack of uniformity of nomenclature for some cell products. Nonetheless, several initiatives to address all of these issues are underway.

Keywords stem cells      clinical trials      funding      animal models      standardization      common definitions     
Corresponding Authors: Viswanathan Sowmya,Email:sowmya.viswanathan@uhnresearch.ca   
Issue Date: 05 December 2011
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-011-0166-2     OR     http://academic.hep.com.cn/fmd/EN/Y2011/V5/I4/333
1 DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22(2): 151-185
doi: 10.1016/S0167-6296(02)00126-1 pmid:12606142
2 DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Cost of innovation in the pharmaceutical industry. J Health Econ 1991; 10(2): 107-142
doi: 10.1016/0167-6296(91)90001-4 pmid:10113009
3 Williams DA, Keating A. Enhancing research in regenerative medicine. Blood 2010; 116(6): 866-867
doi: 10.1182/blood-2010-05-282723 pmid:20705767
4 Group NW. Enhancing Translational Research and Early Phase Trials for Cellular Therapy. Keating AWGC, Editor . 2008. Bethesday, Maryland
5 ICH. Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals (S6), in Safety Guidelines. 1997
6 ICH. Addendum to ICH S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals (S6R1), in Safety Guidelines. 2009
7 FDA.Guidance for Industry: Considerations for Allogeneic Pancreatic Islet Cell Products. 2009
8 FDA. Guidance for Industry: Cellular Therapy for Cardiac Disease. 2010
9 FDA. Draft Guidance for Industry: Preparation of IDEs and INDs for Products Intended to Repair or Replace Knee Cartilage. 2007
10 EMEA. Reflection paper on stem cell-based medicinal products. Therapies CfA, Editor . 2010
11 Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4): 315-317
doi: 10.1080/14653240600855905 pmid:16923606
12 Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ, Krause DS, Keating A. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 2005; 7(5): 393-395
doi: 10.1080/14653240500319234 pmid:16236628
[1] Yingchen Li,Guoheng Hu,Qilai Cheng. Implantation of human umbilical cord mesenchymal stem cells for ischemic stroke: perspectives and challenges[J]. Front. Med., 2015, 9(1): 20-29.
[2] Hai Wang,Qian Zhang,Xiangdong Fang. Transcriptomics and proteomics in stem cell research[J]. Front. Med., 2014, 8(4): 433-444.
[3] Yang Yang, Xiaofei Han, Jingyun Guan, Xiangzhi Li. Regulation and function of histone acetyltransferase MOF[J]. Front Med, 2014, 8(1): 79-83.
[4] Siming Yang, Kui Ma, Changjiang Feng, Yan Wu, Yao Wang, Sha Huang, Xiaobing Fu. Capacity of human umbilical cord-derived mesenchymal stem cells to differentiate into sweat gland-like cells: a preclinical study[J]. Front Med, 2013, 7(3): 345-353.
[5] Siming Yang, Sha Huang, Changjiang Feng, Xiaobing Fu. Umbilical cord-derived mesenchymal stem cells: strategies, challenges, and potential for cutaneous regeneration[J]. Front Med, 2012, 6(1): 41-47.
[6] Zhiyuan Zhang. Bone regeneration by stem cell and tissue engineering in oral and maxillofacial region[J]. Front Med, 2011, 5(4): 401-413.
[7] Shihua Wang, Xuebin Qu, Robert Chunhua Zhao. Mesenchymal stem cells hold promise for regenerative medicine[J]. Front Med, 2011, 5(4): 372-378.
[8] Chuanfeng Wu, Cynthia E. Dunbar. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity[J]. Front Med, 2011, 5(4): 356-371.
[9] Ranhua JIANG, Zhibo HAN, Guangsheng ZHUO, Xiaodan QU, Xue LI, Xin WANG, Yuankang SHAO, Shimin YANG, Zhong Chao HAN. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study[J]. Front Med, 2011, 5(1): 94-100.
[10] Li LI, Jianxin JIANG. Regulatory factors of mesenchymal stem cell migration into injured tissues and their signal transduction mechanisms[J]. Front Med, 2011, 5(1): 33-39.
[11] Yuan YANG, Yi-Min LIU, Ming-Yue WEI, Wei-Ping ZHOU, Hong-Yang WANG, Meng-Chao WU, Yi-Fei WU, Jun-Hui GAO, Lei LIU, . The liver tissue bank and clinical database in China[J]. Front. Med., 2010, 4(4): 443-447.
[12] Wen-Qiang CHEN MD, Yun ZHANG MD, PhD, FACC, . Molecular mechanisms and therapeutic strategies of vulnerable atherosclerotic plaques[J]. Front. Med., 2010, 4(1): 36-42.
[13] YANG Yingzhong, MA Lan, GE Rili, FAN Wenhong, ZHU Lingling, ZHAO Tong, WU Yan, FAN Ming. Effects of hypoxia on mRNA expression of housekeeping genes in rat brain tissue and primary cultured neural cells[J]. Front. Med., 2008, 2(3): 239-243.
[14] SUN Ledong, SUN Jing, ZENG Kang, MENG Fanyi, DIAO Youtao, XU Dan, HUANG Liang, ZHAO Jie, Liu Qifa. Autologous peripheral hematopoietic stem-cell transplantation in a patient with refractory pemphigus[J]. Front. Med., 2008, 2(2): 191-194.
[15] AN Ke, XU Ying, TIAN Xuebi, GAO Feng, TIAN Yuke, YANG Hui, ZHANG Chuanhan. Construction of an immortalized neural progenitor cell strain and analysis of its immunogenicity[J]. Front. Med., 2008, 2(1): 63-69.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed